Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial
Azmi Nasser, Tesfaye Liranso, Toyin Adewole, Nicholas Fry, Joseph T. Hull, Fatima Chowdhry, Gregory D. Busse, Zare Melyan, Andrew J. Cutler, Robert L. Findling, Stefan Schwabe
Topics & Concepts
MedicineRandomized controlled trialPediatricsPhase (matter)Physical therapyInternal medicineOrganic chemistryChemistryAttention Deficit Hyperactivity DisorderAutism Spectrum Disorder ResearchNeurotransmitter Receptor Influence on Behavior